Human papillomavirus vaccination 2020 guideline upda guideline adaptation

Ca-A Cancer Journal for Clinicians 70, 274-280 DOI: 10.3322/caac.21616

Citation Report

#	Article	IF	CITATIONS
1	Reply to The case for catchâ€up human papillomavirus vaccination in atâ€risk populations: Rural communities and survivors of pediatric and young adult cancers. Ca-A Cancer Journal for Clinicians, 2020, 70, 519-520.	157.7	0
2	The Importance of Cancer Screening. Medical Clinics of North America, 2020, 104, 919-938.	1.1	14
3	The case for catchâ€up human papillomavirus vaccination in atâ€risk populations: Rural communities and survivors of pediatric and young adult cancers. Ca-A Cancer Journal for Clinicians, 2020, 70, 518-519.	157.7	4
4	Screening for Cervical Cancer. Medical Clinics of North America, 2020, 104, 1063-1078.	1.1	25
5	Assessing the Long-Term Role of Vaccination against HPV after Loop Electrosurgical Excision Procedure (LEEP): A Propensity-Score Matched Comparison. Vaccines, 2020, 8, 717.	2.1	28
6	Age at Human Papillomavirus Vaccine Initiation Among Adolescents and Young Adults From 22 Pediatric Practices in the Northeastern United States. Journal of Nursing Scholarship, 2021, 53, 46-54.	1.1	2
7	Strategies to improve human papillomavirus vaccination rates among adolescents in family practice settings in the United States: A systematic review. Journal of Clinical Nursing, 2021, 30, 341-356.	1.4	8
8	Cancer Statistics, 2021. Ca-A Cancer Journal for Clinicians, 2021, 71, 7-33.	157.7	12,002
9	Nanomaterials for Protein Delivery in Anticancer Applications. Pharmaceutics, 2021, 13, 155.	2.0	34
10	Including vaccinations in the scope of dental practice. Journal of the American Dental Association, 2021, 152, 184-186.	0.7	11
11	State of the Science: Screening, Surveillance, and Epidemiology of HPV-Related Malignancies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 377-388.	1.8	9
12	Prevalence of cervicovaginal human papillomavirus infection and genotypes in the pre-vaccine era in China: A nationwide population-based study. Journal of Infection, 2021, 82, 75-83.	1.7	22
13	In the Name of Prevention: Maternal Perspectives on School-Based HPV Vaccination in Rural Southern Chile. Adolescent Health, Medicine and Therapeutics, 2021, Volume 12, 27-36.	0.7	2
14	Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For. Journal of Thoracic Oncology, 2021, 16, 546-571.	0.5	25
15	Updated Review of Major Cancer Risk Factors and Screening Test Use in the United States in 2018 and 2019, with a Focus on Smoking Cessation. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1287-1299.	1.1	34
16	A nationwide post-marketing survey of knowledge, attitudes and recommendations towards human papillomavirus vaccines among healthcare providers in China. Preventive Medicine, 2021, 146, 106484.	1.6	9
17	Human Papilloma Virus Vaccination. Viruses, 2021, 13, 1091.	1.5	31
18	Provider-Level Barriers to Human Papillomavirus Vaccination in Survivors of Childhood and Young Adult Cancers. Journal of Adolescent and Young Adult Oncology, 2022, 11, 284-289.	0.7	6

#	Article	IF	CITATIONS
19	Vaccination and their importance for lung transplant recipients in a COVID-19 world. Expert Review of Clinical Pharmacology, 2021, 14, 1413-1425.	1.3	13
20	Single-Dose Human Papillomavirus Vaccination in Low- and Middle-Income Countries—Time for Implementation?. Journal of Pediatric and Adolescent Gynecology, 2021, 34, 586-590.	0.3	2
21	Cancer Equity and Affirming Care: An Overview of Disparities and Practical Approaches for the Care of Transgender, Gender-Nonconforming, and Nonbinary People. Clinical Journal of Oncology Nursing, 2021, 25, 25-35.	0.3	2
22	A National Survey of Obstetrician/Gynecologists' Knowledge, Attitudes, and Beliefs Regarding Adult Human Papillomavirus Vaccination. Journal of Women's Health, 2021, 30, 1476-1484.	1.5	5
23	Vaccination against Cancer or Infectious Agents during Checkpoint Inhibitor Therapy. Vaccines, 2021, 9, 1396.	2.1	5
24	Recommending Human Papillomavirus Vaccination at Age 9: A National Survey of Primary Care Professionals. Academic Pediatrics, 2022, 22, 573-580.	1.0	15
25	Cervical Screening in North Sardinia (Italy): Genotype Distribution and Prevalence of HPV among Women with ASC-US Cytology. International Journal of Environmental Research and Public Health, 2022, 19, 693.	1.2	6
26	Cancer statistics, 2022. Ca-A Cancer Journal for Clinicians, 2022, 72, 7-33.	157.7	10,001
27	Missed Vaccination Opportunities Among U.S. Adolescents by Area Characteristics. American Journal of Preventive Medicine, 2022, 62, 538-547.	1.6	7
28	Cancer statistics for African American/Black People 2022. Ca-A Cancer Journal for Clinicians, 2022, 72, 202-229.	157.7	230
29	Sağlık Hizmetleri Meslek Yüksekokulu Öğrencilerinin Human Papilloma Virüsü (HPV) ve Aşısına Bilgi Düzeyleri ve Sağlık İnançları. İnönü Üniversitesi Sağlık Hizmetleri Meslek Yüksek Oku 10, 180-198.	Yönelik ılwDergisi	, 2022,
30	Empowering Active-Duty Service Members to Initiate the Human Papillomavirus Vaccine. Clinical Journal of Oncology Nursing, 2022, 26, 228-231.	0.3	1
31	Gaps and Opportunities to Improve Prevention of Human Papillomavirus-Related Cancers. Journal of Women's Health, 2021, 30, 1667-1672.	1.5	3
32	Topical aspects of etiology and prevention of cervical cancer. Opuholi Zenskoj Reproduktivnoj Sistemy, 2022, 18, 97-102.	0.1	0
35	Human papillomavirus vaccination for adult women. Revista Brasileira De Ginecologia E Obstetricia, 2022, 44, 631-635.	0.3	0
36	The prevalence of human papillomavirus among women in northern Guangdong Province of China. Scientific Reports, 2022, 12, .	1.6	4
37	Tdap-HPV vaccination bundling in the USA: Trends, predictors, and implications for vaccine series completion. Preventive Medicine, 2022, 164, 107218.	1.6	5
38	Assessing knowledge of human papillomavirus among men who have sex with men (MSM) using targeted dating applications. Vaccine, 2022, 40, 5376-5383.	1.7	2

#	Article	IF	CITATIONS
39	Clinician communication strategies associated with increased uptake of the human papillomavirus (<scp>HPV</scp>) vaccine: A systematic review. Ca-A Cancer Journal for Clinicians, 2022, 72, 561-569.	157.7	12
41	Nomogram models for the prognosis of cervical cancer: A SEER-based study. Frontiers in Oncology, 0, 12, .	1.3	8
42	Identification of Oxidative Stress-Associated Molecular Subtypes and Signature for Predicting Survival Outcome of Cervical Squamous Cell Carcinoma. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-42.	1.9	2
43	HPV Vaccination Initiation and Completion Among Pediatric, Adolescent, and Young Adult Cancer Survivors and a Comparison Population Sample Receiving Primary Care. Journal of Pediatric Hematology/Oncology, 2023, 45, e236-e243.	0.3	2
44	Improving cervical cancer survival–A multifaceted strategy to sustain progress for this global problem. Cancer, 2022, 128, 4074-4084.	2.0	3
45	Cancer statistics for <scp>A</scp> merican <scp>I</scp> ndian and <scp>A</scp> laska <scp>N</scp> ative individuals, 2022: Including increasing disparities in early onset colorectal cancer. Ca-A Cancer Journal for Clinicians, 2023, 73, 120-146.	157.7	39
46	Saudi Healthcare Students' Perceptions and Beliefs About Immunizations: a Descriptive, Cross-Sectional Study. Medicinski Arhiv = Medical Archives = Archives De Médecine, 2022, 76, 458.	0.4	0
47	Cancer prevention in females with and without obesity: Does perceived and internalised weight bias determine cancer prevention behaviour?. BMC Women's Health, 2022, 22, .	0.8	1
48	Genital HPV Prevalence, Follow-Up and Persistence in Males and HPV Concordance Between Heterosexual Couples in Wenzhou, China. Infection and Drug Resistance, 0, Volume 15, 7053-7066.	1.1	0
49	Human papillomavirus vaccination and cervical cancer risk. BMJ, The, O, , e070115.	3.0	20
50	HPV vaccine initiation at 9 or 10 years of age and better series completion by age 13 among privately and publicly insured children in the US. Human Vaccines and Immunotherapeutics, 2023, 19, .	1.4	6
52	Implementing interventions to start HPV vaccination at age 9: Using the evidence we have. Human Vaccines and Immunotherapeutics, 2023, 19, .	1.4	6
53	Engaging health plans to prioritize HPV vaccination and initiate at age 9. Human Vaccines and Immunotherapeutics, 2023, 19, .	1.4	3
54	The association of initiating HPV vaccination at ages 9–10 years and up-to-date status among adolescents ages 13–17 years, 2016-2020. Human Vaccines and Immunotherapeutics, 2023, 19, .	1.4	4
55	HPV Infection and Vaccination: A Question and Answer Guide for School Nurses. NASN School Nurse (Print), 2023, 38, 134-144.	0.4	0
56	Oral Human Papillomavirus Benign Lesions and HPV-Related Cancer in Healthy Children: A Systematic Review. Cancers, 2023, 15, 1096.	1.7	12
57	Multi-level quality improvement strategies to optimize HPV vaccination starting at the 9-year well child visit: Success stories from two private pediatric clinics. Human Vaccines and Immunotherapeutics, 2023, 19, .	1.4	6
58	The trend of change in cervical tumor size and time to death of hospitalized patients in northwestern Ethiopia during 2018–2022: Retrospective study design. Health Science Reports, 2023, 6, .	0.6	6

CITATION REPORT

#	Article	IF	CITATIONS
59	Prevalence and Distribution of High- and Low- Risk HPV Genotypes in Women Living in the Metropolitan Area of Naples: A Recent Update. Asian Pacific Journal of Cancer Prevention, 2023, 24, 435-441.	0.5	1
61	Does HPV vaccination initiation at age 9, improve HPV initiation and vaccine series completion rates by age 13?. Human Vaccines and Immunotherapeutics, 2023, 19, .	1.4	7
62	HPV Vaccination. , 2023, , 209-219.		0
63	Dutch Healthcare Professionals' Opinion on the Allocation of Responsibilities concerning Prescribing and Administering Medically Indicated Vaccines to Immunocompromised Patients. Vaccines, 2023, 11, 686.	2.1	1
64	Recommending HPV vaccination at age 9 to reduce health disparities: Communication challenges and opportunities. Human Vaccines and Immunotherapeutics, 2023, 19, .	1.4	5
65	Using Electronic Reminders to Improve Human Papillomavirus (HPV) Vaccinations among Primary Care Patients. Vaccines, 2023, 11, 872.	2.1	1
72	The major clinical components of cancer immunotherapy (modulating cell-mediated immune) Tj ETQq0 0 0 rgBT	/Overlock	10 Tf 50 502

CITATION REPORT

78	Recent advancement of nanomedicine-based targeted delivery for cervical cancer treatment. , 2023, 40,	0